Piper Sandler Issues Pessimistic Forecast for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price
Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) had its price objective lowered by Piper Sandler from $10.00 to $6.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock. Several other brokerages have also issued reports on LXRX. Leerink Partners reissued a “market perform” rating […]
Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) had its price objective lowered by Piper Sandler from $10.00 to $6.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock. Several other brokerages have also issued reports on LXRX. Leerink Partners reissued a “market perform” rating […]
